One out of eight women will be diagnosed with breast cancer at some point in their lifetime. The scientists at Mirus recognize the need for better research tools to understand the intricacies of this life-altering disease. Mirus Bio has expanded its transfection expertise with the development of a high performance, low toxicity, DNA transfection reagent for breast cancer cell types – TransIT-BrCa Transfection Reagent.
TransIT®-BrCa Transfection Reagent is specifically optimized to provide exceptional transfection efficiency of plasmid DNA in breast cancer and related cell types including: MCF-7, MDA-MB-231 and T47D cells. TransIT-BrCa provides all the attributes of the trusted TransIT series of transfection reagents: high transfection efficiency, low toxicity, serum compatibility, and simplicity of use. Transfections with TransIT-BrCa Reagent do not require medium changes and can be carried out in serum-containing medium. TransIT-BrCa is suitable for both transient and stable transfection and can be used for multiple applications such as gene expression, shRNA expression and promoter analyses.
↓ Mirus TransIT-BrCa Full Transfection Protocol
MIR 5500 | TransIT®-BrCa Transfection Reagent | 1.0 ml |
MIR 5505 | TransIT®-BrCa Transfection Reagent | 5 x 1.0 ml |
MIR 5506 | TransIT®-BrCa Transfection Reagent | 10 x 1.0 ml |